Evidence for protein 4.1B acting as a metastasis suppressor

Journal of Cell Science

Volumn 120, Issue 4, 2007, Pages 606-616

  Cavanna, Tamara ^a   Pokorná, Eva ^b   Veselý, Pavel ^b   Gray, Colin ^a   Zicha, Daniel ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

4.1B protein; Metastasis; Microarray; Migration; Stress fibres

Indexed keywords

F ACTIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN 4.1B; SOMATOMEDIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; IN VITRO STUDY; LEWIS RAT; METASTASIS INHIBITION; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RNA INTERFERENCE; SARCOMA CELL; STRESS FIBER; TISSUE CULTURE;

ANIMALS; CELL LINE, TRANSFORMED; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CHEMOTAXIS; EMBRYO; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROTEIN ARRAY ANALYSIS; RATS; RATS, INBRED LEW; RECOMBINANT FUSION PROTEINS; SARCOMA; STRESS FIBERS;

EID: 33947311207     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.000273     Document Type: Article

References (38)

1. Abroad, A. and Hart, I. R. (1997). Mechanisms of metastasis. Crit. Rev. Oncol. Hematol. 26, 163-173.
2. Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289-300.
3. Bourguignon, L. Y., Zhu, H., Shao, L. and Chen, Y. W. (2000). Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J. Cell Biol. 150, 177-191.
4. Burg, M. A., Grako, K. A. and Stallcup, W. B. (1998). Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiol. 177, 299-312.
5. Charboneau, A. L., Singh, V., Yu, T. and Newsham, I. F. (2002). Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int. J. Cancer 100, 181-188.
6. Chen, B., Blair, D. G., Plisov, S., Vasiliev, G., Perantoni, A. O., Chen, Q., Athanasiou, M., Wu, J. Y., Oppenheim, J. J. and Yang, D. (2004). Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. J. Immunol. 173, 5914-5917.
7. Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T. J., Higgins, D. G. and Thompson, J. D. (2003). Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31, 3497-3500.
8. Clark, E. A., Golub, T. R., Lander, E. S. and Hynes, R. O. (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535.
9. Conboy, J. G. (1993). Structure, function, and molecular genetics of erythroid membrane skeletal protein 4.1 in normal and abnormal red blood cells. Semin. Hematol 30, 58-73.
10. Ein-Dor, L., Zuk, O. and Domany, E. (2006). Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl. Acad. Sci. USA 103, 5923-5928.
11. Fidler, I. J. and Hart, I. R. (1982). Biological diversity in metastatic neoplasms: origins and implications. Science 217, 998-1003.
12. Gascard, P., Parra, M. K., Zhao, Z., Calinisan, V. R., Nunomura, W., Rivkees, S. A., Mohandas, N. and Conboy, J. G. (2004). Putative tumor suppressor protein 4.1B is differentially expressed in kidney and brain via alternative promoters and 5′ alternative splicing. Biochim. Biophys. Acta 1680, 71-82.
13. Gildea, J. J., Seraj, M. J., Oxford, G., Harding, M. A., Hampton, G. M., Moskaluk, C. A., Frierson, H. F., Conaway, M. R. and Theodorescu, D. (2002). RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 62, 6418-6423.
14. Gutmann, D. H., Donahoe, J., Perry, A., Lemke, N., Gorse, K., Kittiniyom, K., Rempel, S. A., Gutierrez, J. A. and Newsham, I. F. (2000). Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum. Mol. Genet. 9, 1495-1500.
15. Gutmann, D. H., Hirbe, A. C., Huang, Z. Y. and Haipek, C. A. (2001). The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol. Dis. 8, 266-278.
16. Khanna, C., Khan, J., Nguyen, P., Prelim, J., Caylor, J., Yeung, C., Trepel, J., Meltzer, P. and Helman, L. (2001). Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 61, 3750-3759.
17. Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M. and Helman, L. J. (2004). The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10, 182-186.
18. Kikuchi, S., Yamada, D., Fukami, T., Masuda, M., Sakurai-Yageta, M., Williams, Y. N., Maruyama, T., Asamura, H., Matsuno, Y., Onizuka, M. et al. (2005). Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin. Cancer Res. 11, 2954-2961.
19. Kikuchi, S., Yamada, D., Fukami, T., Maruyama, T., Ito, A., Asamura, H., Matsuno, Y., Onizuka, M. and Murakami, Y. (2006). Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer 106, 1751-1758.
20. Kittiniyom, K., Gorse, K. M., Dalbegue, F., Lichy, J. H., Taubenberger, J. K. and Newsham, I. F. (2001). Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res. 3, 192-198.
21. Kuno, K., Bannai, K., Hakozaki, M., Matsushima, K. and Hirose, K. (2004). The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem. Biophys. Res. Commun. 319, 1327-1333.
22. Lee, J. E., Kim, H. J., Bae, J. Y., Kim, S. W., Park, J. S., Shin, H. J., Han, W., Kang, K. S. and Noh, D. Y. (2005). Neogenin expression may be inversely correlated to the tumorigenicity of human breast cancer. BMC Cancer 5, 154.
23. Parra, M., Gascard, P., Walensky, L. D., Snyder, S. H., Mohandas, N. and Conboy, J. G. (1998). Cloning and characterization of 4.1G (EPB41L2), a new member of the skeletal protein 4.1 (EPB41) gene family. Genomics 49, 298-306.
24. Peracaula, R., Cleary, K. R., Lorenzo, J., de Llorens, R. and Frazier, M. L. (2000). Human pancreatic ribonuclease 1, expression and distribution in pancreatic adenocarcinoma. Cancer 89, 1252-1258.
25. Pokorna, E., Jordan, P. W., O'Neill, C. H., Zicha, D., Gilbert, C. S. and Vesely, P. (1994). Actin cytoskeleton and motility in rat sarcoma cell populations with different metastatic potential. Cell Motil. Cytoskeleton 28, 25-33.
26. Ramaswamy, S., Ross, K. N., Lander, E. S. and Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54.
27. Sahai, E., Wyckoff, J., Philippar, U., Segall, J. E., Gertler, F. and Condeelis, J. (2005). Simultaneous imaging of GFP, CFP and collagen in tumors in vivo using multiphoton microscopy. BMC Biotechnol. 5, 14.
28. Syed, N., Smith, P., Sullivan, A., Spender, L. C., Dyer, M., Karran, L., O'Nions, J., Allday, M., Hoffmann, I., Crawford, D. et al. (2006). Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107, 250-256.
29. Topol, L. Z., Marx, M., Laugier, D., Bogdanova, N. N., Boubnov, N. V., Clausen, P. A., Calothy, G. and Blair, D. G. (1997). Identification of drm, a novel gene whose expression is suppressed in transformed cells and which can inhibit growth of normal but not transformed cells in culture. Mol. Cell. Biol. 17, 4801-4810.
30. Tran, Y. K., Bogler, O., Gorse, K. M., Wieland, I., Green, M. R. and Newsham, I. F. (1999). A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 59, 35-43.
31. Vallenius, T., Scharm, B., Vesikansa, A., Luukko, K., Schafer, R. and Makela, T. P. (2004). The PDZ-LIM protein RIL modulates actin stress fiber turnover and enhances the association of alpha-actinin with F-actin. Exp. Cell Res. 293, 117-128.
32. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J. et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009.
33. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T. et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
34. Vesely, P. and Weiss, R. A. (1973). Cell locomotion and contact inhibition of normal and neoplastic rat cells. Int. J. Cancer 11, 64-76.
35. Vesely, P., Chaloupkova, A., Urbanec, P., Urbancova, H., Bohac, L., Krchnakova, E., Franc, F., Sprincl, L., Vousden, K., Moss, R. et al. (1987). Patterns of in vitro behaviour characterizing cells of spontaneously metastasizing K2M rat sarcoma. Folia Biol. Praha 33, 307-324.
36. Wyckoff, J. B., Jones, J. G., Condeelis, J. S. and Segall, J. E. (2000). A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. 60, 2504-2511.
37. Zicha, D. and Dunn, G. A. (1995). Are growth factors chemotactic agents? Exp. Cell Res. 221, 526-529.
38. Zicha, D., Dunn, G. A. and Brown, A. F. (1991). A new direct-viewing chemotaxis chamber. J. Cell Sci. 99, 769-775.